Som Mukherjee
Hamilton Health Sciences Corporation · Juravinski Cancer Centre at Hamilton Health Sciences Centre, ON Canada · Juravinski Cancer Centre
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Som Mukherjee as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:12 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04680442 · Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular DysfunctionPopulation Health Research Institute · recruiting · Breast Cancer, Heart Failure · principal investigator
- Ph2NCT03385655 · Prostate Cancer Biomarker Enrichment and Treatment SelectionCanadian Cancer Trials Group · active not recruiting · Prostate Cancer · study chair
- N/ANCT02462239 · Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder StagingOntario Clinical Oncology Group (OCOG) · completed · Muscle-invasive Bladder Cancer · principal investigator
- N/ANCT01240681 · Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI) and Fluorothymidine Positron Emission Tomography (FLT PET) in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant ChemotherapyOntario Clinical Oncology Group (OCOG) · completed · Locally Advanced Breast Cancer (LABC) · principal investigator
- N/ANCT00788489 · A Prospective Study to Evaluate FDG-PET, Breast MRI, and Breast Ultrasonography in Monitoring Tumour Responses in Patients With Locally Advanced Breast Cancer (LABC) Undergoing Neoadjuvant ChemotherapyOntario Clinical Oncology Group (OCOG) · completed · Locally Advanced Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 21:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 21:12 UTC. The ranking covers the 200 most relevant of 183 PubMed records, and a shared surname and initials can bring in a namesake. All 183 on PubMed
- Abiraterone in metastatic prostate cancer without previous chemotherapy.N Engl J Med · 20132,334 citationsRCR 67.7
- CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea.N Engl J Med · 20161,631 citationsRCR 69.8
- Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.N Engl J Med · 2023529 citationsRCR 41.5
- 415 citationsRCR 15.5
- Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.J Clin Oncol · 2023312 citationsRCR 23.9
- Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.Lancet Oncol · 2013311 citationsRCR 8.8
- Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.Lancet Gastroenterol Hepatol · 2023306 citationsRCR 30.4
- Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.Lancet Oncol · 2013275 citationsRCR 8.1
- 205 citationsRCR 14.5
- Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.Lancet Oncol · 2007156 citationsRCR 3.1